Achillion Pharmaceuticals Inc. (NASDAQ: ACHN) announced updated interim results from its ongoing interferon-free, ribavirin-free Phase 2 study evaluating ACH-3102 and sofosbuvir. Sofosbuvir is a marketed nucleotide polymerase inhibitor. Ultimately the results were positive and the stock is seeing a solid boost in Monday’s trading.
According to the press release:
The primary objective of the study is determination of sustained viral response 12 weeks (SVR12) after completion of therapy. One hundred percent of patients (12/12) in the six-week treatment duration arm achieved SVR12, which included patients with high baseline viral load.
After achieving 100% SVR12 (12/12) in the eight-week cohort, the six-week treatment cohort was initiated. A total of 18 patients were enrolled, including 12 active and six observational patients. Of the 12 active patients enrolled, seven patients were genotype 1a and five were genotype 1b for hepatitis C.
Twelve weeks after the completion of therapy, 100% (12/12) achieved SVR12, independent of baseline viral load, gender and IL28B status, in the six-week treatment arm. Additionally, 100% of patients (12/12) in the eight-week treatment duration arm had achieved SVR24. Overall, the combination of ACH-3102 and sofosbuvir was well-tolerated with no serious adverse events, no discontinuations due to adverse events and no clinically significant laboratory or ECG abnormalities.
ALSO READ: 5 Top Credit Suisse Health Care Stock Picks to Buy for 2015
Looking ahead to the next step, Dr. David Apelian, Executive Vice President of Clinical Development and Chief Medical Officer at Achillion, said:
We are currently preparing to initiate our SPARTA Phase 2 program which evaluates short treatment durations with our proprietary once-daily regimens of ACH-3102 and ACH-3422, with or without sovaprevir, for treatment naive genotype 1 HCV patients. In parallel, we plan on exploring sofosbuvir-sparing regimens that will leverage shorter durations of sofosbuvir in combination with ACH-3102 and sovaprevir as part of our global development program.
Shares of Achillion were up about 12% at $12.16 in Monday’s premarket trading and opened at $12.09. The stock has a consensus analyst price target of $20.06 and a 52-week trading range of $2.45 to $16.00.
Take Charge of Your Retirement In Just A Few Minutes (Sponsor)
Retirement planning doesn’t have to feel overwhelming. The key is finding expert guidance—and SmartAsset’s made it easier than ever for you to connect with a vetted financial advisor.
Here’s how it works:
- Answer a Few Simple Questions. Tell us a bit about your goals and preferences—it only takes a few minutes!
- Get Matched with Vetted Advisors Our smart tool matches you with up to three pre-screened, vetted advisors who serve your area and are held to a fiduciary standard to act in your best interests. Click here to begin
- Choose Your Fit Review their profiles, schedule an introductory call (or meet in person), and select the advisor who feel is right for you.
Why wait? Start building the retirement you’ve always dreamed of. Click here to get started today!
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
Our expert who first called NVIDIA in 2009 is predicting 2025 will see a historic AI breakthrough.
You can follow him investing $500,000 of his own money on our top AI stocks for free.